二肽基肽酶4抑制剂对心血管疾病的潜在影响

被引：1

作者：

陈静

陈宇红

机构：

[1] 上海交通大学医学院附属瑞金医院内分泌代谢病科上海市内分泌代谢病临床医学中心上海市内分泌代谢病研究所

来源：

内科理论与实践 | 2014年 / 01期

关键词：

二肽基肽酶4; 二肽基肽酶4抑制剂; 心血管疾病;

D O I：

暂无

中图分类号：

R54 [心脏、血管（循环系）疾病]; R587.1 [糖尿病];

学科分类号：

1002 ; 100201 ;

摘要：

<正>鉴于2型糖尿病患者胰岛β细胞功能渐进性下降的特质及各种不良反应,如低血糖、体重增加、水肿等导致抗糖尿病药物使用受到限制,且目前的降糖药物对餐后血糖的控制力度不足,在美国,不到半数糖尿病患者血糖控制能达标[糖化血红蛋白(HbA1c)<7%][1]。而有研究证明餐后血糖是心血管疾病的一个独立危险因素[2],甚至可以预测心血管疾病的发生[3]。长达20年的美国Framingham队列研究报道,糖尿病患者动脉粥样硬化发病风险增加2～3倍[4]。糖尿病患者

引用

页码：79 / 83

页数：5

共 22 条

[1]

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes[J] . Maria Rosaria Rizzo,Michelangela Barbieri,Raffaele Marfella,Giuseppe Paolisso.Diabetes Care . 2012 (10)

[2]

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease[J] . Jixin Zhong,Xiaoquan Rao,Sanjay Rajagopalan.Atherosclerosis . 2012

[3] Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors [J].

Chrysant, Steven G. ;

Chrysant, George S. .

AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (11) :1681-1685

[4]

A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice[J] . Junichi Matsubara,Seigo Sugiyama,Koichi Sugamura,Taishi Nakamura,Yukio Fujiwara,Eiichi Akiyama,Hirofumi Kurokawa,Toshimitsu Nozaki,Keisuke Ohba,Masaaki Konishi,Hirofumi Maeda,Yasuhiro Izumiya,Koichi Kaikita,Hitoshi Sumida,Hideaki Jinnouchi,Kunihiko Matsui,Shokei Kim-Mitsuyama,Motohiro Takeya,Hisao Ogawa.Journal of the Ameri

[5] Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis [J].

Shah, Zubair ;

Kampfrath, Thomas ;

Deiuliis, Jeffrey A. ;

Zhong, Jixin ;

Pineda, Colleen ;

Ying, Zhekang ;

Xu, Xiaohua ;

Lu, Bo ;

Moffatt-Bruce, Susan ;

Durairaj, Rekha ;

Sun, Qinghua ;

Mihai, Georgeta ;

Maiseyeu, Andrei ;

Rajagopalan, Sanjay .

CIRCULATION, 2011, 124 (21) :2339-U135

[6]

Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1[J] . Gian Paolo Fadini,Angelo Avogaro.Vascular Pharmacology . 2011 (1)

[7] Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans [J].

Marney, Annis ;

Kunchakarra, Siri ;

Byrne, Loretta ;

Brown, Nancy J. .

HYPERTENSION, 2010, 56 (04) :728-U298

[8] DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes [J].

Ta, Nga N. ;

Li, Yanchun ;

Schuyler, Corinne A. ;

Lopes-Virella, Maria F. ;

Huang, Yan .

ATHEROSCLEROSIS, 2010, 213 (02) :429-435

[9] Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema [J].

Brown, Nancy J. ;

Byiers, Stuart ;

Carr, David ;

Maldonado, Mario ;

Warner, Barbara Ann .

HYPERTENSION, 2009, 54 (03) :516-U141

[10]

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension[J] . Goutam C. Mistry,Andrea L. Maes,Kenneth C. Lasseter,Michael J. Davies,Keith M. Gottesdiener,John A. Wagner,Gary A. Herman.Journal of Clinical Pharmacology . 2008 (5)

← 1 2 3 →